A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

September 30, 2016

Conditions
Parkinson's Disease
Interventions
DRUG

PXT002331

Trial Locations (1)

Unknown

United Kingdom, United Kingdom

Sponsors
All Listed Sponsors
lead

Prexton Therapeutics

INDUSTRY